FDMT
Price
$11.85
Change
-$0.77 (-6.10%)
Updated
Oct 22 closing price
Capitalization
654.64M
17 days until earnings call
Intraday BUY SELL Signals
IFRX
Price
$1.53
Change
-$0.02 (-1.29%)
Updated
Oct 22 closing price
Capitalization
225.47M
17 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

FDMT vs IFRX

FDMT vs IFRX Comparison Chart in %
View a ticker or compare two or three
VS
FDMT vs. IFRX commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FDMT is a StrongBuy and IFRX is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for FDMT with price predictions
Oct 22, 2026

FDMT's RSI Oscillator ascends from oversold territory

The RSI Indicator for FDMT moved out of oversold territory on October 08, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In 24 of the 28 cases the stock moved higher. This puts the odds of a move higher at 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 58 cases where FDMT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.

Following a +7.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where FDMT advanced for three days, in 216 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

FDMT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FDMT as a result. In 73 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.

The Moving Average Convergence Divergence Histogram (MACD) for FDMT turned negative on September 24, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 36 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.

FDMT moved below its 50-day moving average on October 05, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for FDMT crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 58%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FDMT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

The Aroon Indicator for FDMT entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.606) is normal, around the industry mean (2.973). P/E Ratio (-4.506) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (9.662) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. FDMT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 49 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FDMT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for IFRX with price predictions
Oct 22, 2026

IFRX's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for IFRX turned positive on October 21, 2026. Looking at past instances where IFRX's MACD turned positive, the stock continued to rise in 44 of 50 cases over the following month. The odds of a continued upward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IFRX's RSI Indicator exited the oversold zone, 25 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 63 of 74 cases where IFRX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.

The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on IFRX as a result. In 84 of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.

Following a +6.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where IFRX advanced for three days, in 185 of 229 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

IFRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

IFRX moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for IFRX crossed bearishly below the 50-day moving average on September 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 20 of 24 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IFRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for IFRX entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.542) is normal, around the industry mean (2.973). P/E Ratio (-3.060) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. IFRX's P/S Ratio (3333.333) is slightly higher than the industry average of (438.009).

The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. IFRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IFRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
FDMT vs IFRX: Fundamental Ratings
FDMT
IFRX
OUTLOOK RATING
1..100
6065
VALUATION
overvalued / fair valued / undervalued
1..100
25
Undervalued
2
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
4563
P/E GROWTH RATING
1..100
4924
SEASONALITY SCORE
1..100
75n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IFRX's Valuation (2) in the Biotechnology industry is in the same range as FDMT (25) in the null industry. This means that IFRX’s stock grew similarly to FDMT’s over the last 12 months.

IFRX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as FDMT (100) in the null industry. This means that IFRX’s stock grew similarly to FDMT’s over the last 12 months.

IFRX's SMR Rating (97) in the Biotechnology industry is in the same range as FDMT (97) in the null industry. This means that IFRX’s stock grew similarly to FDMT’s over the last 12 months.

FDMT's Price Growth Rating (45) in the null industry is in the same range as IFRX (63) in the Biotechnology industry. This means that FDMT’s stock grew similarly to IFRX’s over the last 12 months.

IFRX's P/E Growth Rating (24) in the Biotechnology industry is in the same range as FDMT (49) in the null industry. This means that IFRX’s stock grew similarly to FDMT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FDMTIFRX
RSI
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
83%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
82%
MACD
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 3 days ago
81%
Declines
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 8 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
83%
Aroon
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
89%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (FDMT: $11.85 vs. IFRX: $1.53)
Brand notoriety: FDMT and IFRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FDMT: 111% vs. IFRX: 51%
Market capitalization -- FDMT: $654.64M vs. IFRX: $225.47M
FDMT [@Biotechnology] is valued at $654.64M. IFRX’s [@Biotechnology] market capitalization is $225.47M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FDMT’s FA Score shows that 1 FA rating(s) are green while IFRX’s FA Score has 2 green FA rating(s).

  • FDMT’s FA Score: 1 green, 4 red.
  • IFRX’s FA Score: 2 green, 3 red.
According to our system of comparison, FDMT is a better buy in the long-term than IFRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FDMT’s TA Score shows that 4 TA indicator(s) are bullish while IFRX’s TA Score has 6 bullish TA indicator(s).

  • FDMT’s TA Score: 4 bullish, 6 bearish.
  • IFRX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, IFRX is a better buy in the short-term than FDMT.

Price Growth

FDMT (@Biotechnology) experienced а -7.93% price change this week, while IFRX (@Biotechnology) price change was +6.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.

Reported Earning Dates

FDMT is expected to report earnings on Nov 09, 2026.

IFRX is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Biotechnology (-1.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
FDMT
Daily Signal:
Gain/Loss:
IFRX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

FDMT and

Correlation & Price change

A.I.dvisor indicates that over the last year, FDMT has been loosely correlated with KYTX. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if FDMT jumps, then KYTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FDMT
1D Price
Change %
FDMT100%
-6.10%
KYTX - FDMT
60%
Loosely correlated
-1.88%
RCKT - FDMT
55%
Loosely correlated
+5.00%
SLDB - FDMT
52%
Loosely correlated
-3.43%
PRME - FDMT
52%
Loosely correlated
-2.10%
EDIT - FDMT
51%
Loosely correlated
-0.80%
More

IFRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IFRX has been loosely correlated with KURA. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if IFRX jumps, then KURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IFRX
1D Price
Change %
IFRX100%
-1.29%
KURA - IFRX
40%
Loosely correlated
-0.20%
VIR - IFRX
37%
Loosely correlated
-1.32%
SGMT - IFRX
36%
Loosely correlated
-0.40%
DSGN - IFRX
36%
Loosely correlated
-2.24%
FDMT - IFRX
35%
Loosely correlated
-6.10%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CZA124.791.62
+1.31%
Invesco Zacks Mid-Cap ETF (CZA)
SMBS24.470.19
+0.76%
Schwab Mortgage-Backed Securities ETF (SMBS)
PSK28.050.12
+0.43%
State Street SPDR ICE Preferred Securities ETF (PSK)
XCNY32.37-0.90
-2.69%
State Street SPDR S&P Emerging Markets ex-China ETF (XCNY)
QQQT17.10-0.50
-2.83%
Defiance Nasdaq 100 Income Target ETF (QQQT)